ClinicalTrials.gg
CompletedNCT01380457Updated Jun 27, 2011

Bioavailability Study of Dronabinol Capsules 10 mg Under Fasting Conditions

A Phase 1 interventional study of Dronabinol and Marinol in To Determine Bioequivalence Under Fasting Conditions, sponsored by Par Pharmaceutical, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-06-27.

Sponsored by Par Pharmaceutical, Inc. (part of Par Health) · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
69
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies in Fasting by Par Health — none open to participants now, none under way, none of them phase 3. Fasting · Par Health.

Enrollment
Largest of 19
69 · median 32
Started
2006
the only one that year
Phase 1
18 of 19
none open now
Registered
18th of 19
by date

Among the 19 studies in Fasting by Par Health, this one has the largest enrollment, is the only one that started in 2006, is one of 18 in phase 1, and was the 18th registered.

Fasting

392 studies on the registry are indexed under Fasting; 63 are open to participants now.

Browse Fasting studies →

Open to participants now

None of the 19 studies in Fasting by Par Health is open now. The open studies under Fasting, anywhere →

Where they have run

Who these studies take

Of the 45 Fasting studies recruiting now, 15 (33%) set no upper age limit and 24 (53%) stop at 75 or younger; 7 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies in Fasting by Par Health as a file.
02

Study summary

The purpose of this study is to compare the rate and extent of absorption of Dronabinol 10 mg capsules verses Marinol.

Read the detailed description

To compare the plasma levels of dronabinol (delta-9-tetrahydrocannabinol)and the principle active metabolite 11-OH-delta-9-tetrahydrocannabinol levels produced after administration of the test formulation with those produced after administration of a marketed reference product, under fasted conditions.

03

Conditions studied

  • To Determine Bioequivalence Under Fasting Conditions

Browse trials for

Keywords

  • bioequivalence
  • dronabinol
  • fasting
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy volunteers, 18 - 55 years of age
  • Subjects must be within 18 to 29.9 kilograms/m2 per the
  • General good health as determined by medical history and physical examination within 30 days prior to the start of the study
  • Blood chemistry, hematology, and urinalysis tests will be performed within 30 days prior to the start of the study
  • No participation in an drug study or donation of blood within 30 days prior to the start of the study
  • At screening, subjects must have blood pressure and pulse rate within specified ranges
  • No grapefruit juice or grapefruit-containing products for at least 72 hours prior to drug administration, each period. Subjects will be queried at check-in each period on consumption of grapefruit juice or grapefruit containing products. Results will be recorded and reported in the final report.
  • No alcohol consumption for at least 24 hours prior to drug administration, each period
  • No caffeine or xanthine consumption for 48 hours prior prior to drug administration, each period
  • No prescription drugs (excluding hormonal ) within 14 days prior to drug administration, each period
  • Subjects should refrain from taking OTC preparations, and/or nutritional supplements within 7 days prior to drug administration, each period. Subjects shall refrain from taking herbal remedies within 14 day prior to drug administration, and throughout the study periods
  • Female subjects must not be pregnant or nursing; and must be surgically sterile; one year ; or on hormonal contraceptive agents), a diaphragm or condom with spermicidal foam or jelly, or IUD for at least 3 months prior to drug administration and agree to use the same method of contraception for at least 1 month after the last drug administration
  • Negative serum pregnancy test at screening and negative urine pregnancy test prior to drug administration, each period
  • Negative 1, surface antigen, an urine screen for drugs of abuse within 30 days prior to the start of the study

Exclusion criteria

Exclusion Criteria:

  • Disease or condition that could impact interpretation of study results or a condition which treatment would be per currently approved product labeling
  • Subjects had any of the following conditions:

    • used any prescription or OTC medication within 14 days of study initiation
    • a positive urine test for illicit drugs
    • participated in a clinical investigation within the past 30 days
    • had allergies to drugs or foods, ot
    • any condition that might place them at increased risk of complications
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
69 participants (actual)

Study arms

  • Experimental
    A

    Subjects received the test formulated product manufactured by Pharmaceutics International, Inc. and marketed by Par Pharmaceutical, Inc. under fasting conditions

    Drug: Dronabinol

  • Active comparator
    B

    Subjects received the reference listed drug manufactured by Banner Pharmacaps, Inc. and marketed by Unimed Pharmaceutical, Inc.

    Drug: Marinol

Interventions

  • Capsules, 10 mg, single dose, fasting conditions

    Also known as: Marinol

  • Capsules, 10 mg, single-dose, fasting conditions

    Also known as: Dronabinol

06

What researchers measure

Primary outcomes

  1. Bioequivalence

    To conclude bioequivalence; 90% geometric confidence interval was contained within the limits 0.8 to 1.25.

07

Study locations

1 site
  • BASi
    Baltimore, Maryland 21201, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2006, a primary completion of Apr 2006 and a completion of Apr 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2011
First posted
Jun 27, 2011
Start
Jan 2006
Primary completionActual
Apr 2006
CompletionActual
Apr 2006
Last update
Jun 27, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 27, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01380457
Collaborators
BASi Clinical Research Unit
First posted
Jun 27, 2011
Start date
Jan 2006
Primary completion
Apr 2006
Completion
Apr 2006
Last update
Jun 27, 2011

Study contacts

Dilip K Guha-Ray, M.D.
principal investigator · BASi Baltimore Clinical Research Unit

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dronabinol

Start the discussion